非小细胞肺癌免疫治疗进展徐燕.pdf

34 · · 中国肺癌杂志2 0 4 年 月第 7 卷第 期 Chin J Lung Cancer, Januar y 20 4, Vol. 7, No.  DOI: 0.3779/j.issn. 009-349.204.0 .06 · 综 述 · 非小细胞肺癌免疫治疗进展 徐燕 综述 王孟昭 审校 【摘要】近年来，非小细胞肺癌（non-small cell lung cancer, NSCLC ）在手术治疗、放疗、化疗及靶向治疗方面 NSCLC 5 均取得了很大的进展，但晚期 患者的 年生存率仍然很低。免疫治疗利用免疫系统来控制和清除瘤细胞，已 成为肿瘤治疗的一种重要手段。NSCLC 的免疫治疗近期取得了突破性的进展，抗原特异性肿瘤疫苗、检查点阻滞 剂等多种新型抗肿瘤免疫治疗药物已进行NSCLC治疗的临床试验，并在II期和III期临床试验中取得一定的成果。目 前已完善了免疫治疗疗效评估标准，成为免疫治疗药物抗肿瘤评价标准。免疫治疗将成为NSCLC治疗的一种重要 手段。 【关键词 】肺肿瘤；免疫治疗；肿瘤疫苗；调定点阻滞剂 Progress in Immunotherapy for Non-small Cell Lung Cancer Yan XU, Mengzhao WANG Department of Respiratory Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China Corresponding author: Mengzhao WANG, E-mail: mengzhaowang@ Abstract In recent years, the five-year survival rate of patients with advanced stage non-small cell lung cancer 【 】 (NSCLC) remains low despite recent advances in surgery, irradiation, chemotherapy, and targeted therapy. Immunotherapy which utilizes the immune system to control and eradicate cancer is a viable treatment approach for malignancy. Immunother- apy in patients with lung cancer has made breakthrough progress recently. Novel immunotherapeutic agents, such as antigen- specific tumour vaccines, checkpoint inhibitors, etc, have all been evaluated in lung cancer, and some have shown prolonged survi